Sponsor: Abbvie
Phase of Development: III
Study duration: 1-6 months
Enrollment: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Sponsor: Abbvie
Phase of Development: III
Study duration: 1-6 months
Enrollment: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Sponsor: Abbvie
Phase of Development: III
Study duration: 12 months
Enrollment: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Sponsor: Eli Lilly Pharmaceuticals
Phase of Development: Phase III
Study Duration: Up to 12 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Sponsor: Eli Lilly Pharmaceuticals
Phase of Development: Phase III
Study Duration: 52 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Sponsor: Eli Lilly Pharmaceuticals
Phase of Development: Phase III
Study Duration: 18 Months
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Sponsor: Eli Lilly Pharmaceuticals
Phase of Development: Phase III
Study Duration: 18 Months
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
M22-418: A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine
Sponsor: AbbVie
Phase of Development: Phase III
Study Duration: Approximately 40 weeks
Enrollment Status: Open – Estimated end of screening in August 2024
Principal Investigator: Rajiv Aggarwal, M.D.
XPF-010-301 (X-TOLE2): A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Seizures
Sponsor: Xenon Pharmaceuticals, Inc.
Phase of Development: Phase III
Study Duration: Up to 6.5 months
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Sponsor: Xenon Pharmaceuticals, Inc.
Phase of Development: Phase III
Study Duration: Approximately 1 year
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
XPF-010-301 (X-TOLE2): A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Seizures
Sponsor: Xenon Pharmaceuticals, Inc.
Phase of Development: Phase III
Study Duration: Up to 6.5 months
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
XPF-010-304 (X-TOLE4): A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy
Sponsor: Xenon Pharmaceuticals, Inc.
Phase of Development: Phase III
Study Duration: Approximately 1 year
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Sponsor: Ipsen Innovation
Phase of Development: Phase III
Study Duration: Up to 60 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Research Contacts: Dr. Aggarwal or Madison Irwin, Clinical Research Coordinator, 763-302-4162 or Madison.Irwin@mpls-clinic.com, or David Harvey, MN, RN, Clinical Research Nurse, 763-302-4359 or David.Harvey@mpls-clinic.com.
Important Information:
A description of all the clinical trials stated above are available on https://clinicaltrials.gov/, as required by U.S. Law.
All epilepsy clinical trials being conducted at the Minneapolis Clinic of Neurology are approved by an independent ethics committee called an Institutional Review Board (IRB). An IRB is a type of committee used in research in the United States that has been formally designated to approve, monitor, and review biomedical and behavioral research involving human subjects. The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of human subjects participating in a research study.
XPF-010-301 (X-TOLE2): A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XENl 101 as Adjunctive Therapy in Focal Onset Seizures Sponsor: Xenon Pharmaceuticals, Inc.
Phase of Development: Phase III Study Duration: Up to 6.5 months Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
XPF-010-304 (X-TOLE4): A Randomized, Double-blind, Placebo-Controlled, Multicenter, Open-label, Long term, Safety, Tolerability, and Efficacy Study of XENl 101 in Adults Diagnosed With Epilepsy
Sponsor: Xenon Pharmaceuticals, Inc.
Phase of Development: Phase III Study Duration: Approximately 1 year Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
CLIN-52120-463: A Phase III, Randomised, Double-Blind, Placebo-controlled, Multicentre, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants
Sponsor: Ipsen Innovation
Phase of Development: Phase III
Study Duration: Up to 60 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
CLIN-52120-464: A Phase III, Randomised, Double-Blind, Placebo-controlled, Multicentre, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants
Sponsor: Ipsen Innovation
Phase of Development: Phase III
Study Duration: Up to 60 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Research Contacts: Dr. Aggarwal or Madison Irwin, Clinical Research Coordinator, 763-302-4162 or Madison.Iiwin@mpls-clinic.com, or David Harvey, MN, RN, Clinical Research Nurse, 763-302-4359 or David.Harvey@mpls-clinic.com.